<DOC>
	<DOCNO>NCT01696370</DOCNO>
	<brief_summary>Hypertrophic cardiomyopathy ( HCM ) common inherited heart condition cause breathlessness , chest pain fatigue . There treatment available . The investigator recently show drug call perhexiline reduce symptom improve exercise capacity patient HCM . This change appear driven alteration myocardial energy metabolism . The aim trial test similar drug , trimetazidine , group symptomatic patient non-obstructive HCM . HYPOTHESIS : trimetazidine improve symptom , peak oxygen consumption , cardiac function arrhythmia burden medically refractory symptomatic patient non-obstructive HCM .</brief_summary>
	<brief_title>Trimetazidine Therapy Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description>BACKGROUND : Hypertrophic cardiomyopathy ( HCM ) common inherit disorder heart muscle affect 1 500 individual worldwide . It associate arrhythmias , heart failure sudden death young people . In majority patient , HCM cause mutation gene encode cardiac contractile protein . It hypothesise excessive sarcomeric energy consumption important early factor pathophysiology HCM . Therefore modulation myocardial metabolism present novel target improve myocardial performance symptom patient HCM . Trimetazidine anti-anginal agent like perhexiline reduces fatty acid oxidation increase glucose oxidation , thus increase efficiency energy production . Trimetazidine show significantly improve exercise performance patient stable angina , ischaemic non ischaemic cardiomyopathy , either monotherapy combination beta-blockers calcium channel blocker , DESIGN : A single centre prospective randomise , double blind , placebo-controlled , trial trimetazidine therapy . DOSING : 20 mg Trimetazidine Placebo three time daily three month METHODS : The following assessment make baseline 3 month treatment : history physical examination , Minnesota heart failure questionnaire , fast blood test , electrocardiogram , echocardiogram , cardiopulmonary exercise test , six minute walk test , 24 hour ECG Holter monitor .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Trimetazidine</mesh_term>
	<criteria>Nonobstructive hypertrophic cardiomyopathy ( gradient &lt; 30 mmHg rest ) NYHA ( New York Heart Association ) Class ≥ 2 Peak VO2 ( maximal oxygen consumption ) ≤80 % predict age gender Heart rate &lt; 90/minute rest Diabetes Mellitus Abnormal renal function ( GFR &lt; 60ml/min ) hepatic impairment Female pregnant , lactate plan pregnancy course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Trimetazidine</keyword>
</DOC>